CalciMedica, Inc. (CALC)
Nasdaq · Healthcare · Biotechnology
$1.54−3.45%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $10.5M
- 52-week range
- $1.54 – $36.00
- 52-week change
- −90.56%
- EPS (trailing)
- −$6.85
Fiscal year to Dec 2025
- Net income
- −$29.6M
- Diluted EPS
- −$1.97
- Free cash flow
- −$21.2M
From the company’s annual report on SEC EDGAR.
About CalciMedica, Inc.
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.
Headquarters: La Jolla, United States · 15 employees · calcimedica.com